Lobe Sciences Ltd. (LOBEF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lobe Sciences Ltd. (LOBEF) trades at $0.0559. Lobe Sciences Ltd. is a biopharmaceutical company focused on developing psychedelic medicines for treating traumatic brain injuries and PTSD. Market cap: $15.9M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for LOBEF: LOBEF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LOBEF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on LOBEF.
How is this calculated? →Lobe Sciences Ltd. (LOBEF) Healthcare & Pipeline Overview
Lobe Sciences Ltd. is a Canadian life sciences company focused on the research and development of psychedelic medicines, specifically psilocybin-based therapeutics, for treating mild traumatic brain injuries and post-traumatic stress disorder. The company also develops devices for efficient drug application within the specialty pharmaceutical sector.
What Is the Investment Thesis for LOBEF?
Lobe Sciences Ltd. presents a speculative investment opportunity within the emerging psychedelic medicine market. The company's focus on developing psilocybin-based therapeutics for mTBI and PTSD addresses significant unmet medical needs. Key value drivers include successful completion of clinical trials and regulatory approvals for its drug candidates. The company's research and development efforts, particularly the combination of psilocybin with NAC, could lead to novel and effective treatments. Growth catalysts include advancing its drug pipeline through clinical phases, securing partnerships with established pharmaceutical companies, and expanding its intellectual property portfolio. The company's current P/E ratio is -4.12. Potential risks include regulatory hurdles, clinical trial failures, competition from other companies in the psychedelic medicine space, and the inherent volatility of the OTC market.
Based on FMP financials and quantitative analysis
LOBEF Key Highlights
Lobe Sciences Ltd. focuses on developing psilocybin-based therapeutics for mild traumatic brain injuries and post-traumatic stress disorder.
- The company is also developing devices for the efficient application of medications, potentially improving drug delivery and patient outcomes.
- Lobe Sciences changed its name from Greenstar Biosciences Corp. in November 2020, reflecting its strategic shift towards psychedelic medicine.
- The company's research involves combining psilocybin with N-acetylcysteine (NAC) to enhance therapeutic effects.
- Lobe Sciences operates in the emerging psychedelic medicine market, which is subject to evolving regulations and scientific advancements.
Who Are LOBEF's Competitors?
LOBEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BBRRF Blueberries Medical Corp. | $0.01 | +16.79% | $6.13M | 59 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LOBEF's Key Strengths?
Focus on a high-growth market (psychedelic medicine).
- Novel therapeutic approach combining psilocybin with NAC.
- Development of innovative drug delivery systems.
- Experienced management team with expertise in drug development.
What Are LOBEF's Weaknesses?
Early-stage company with limited revenue.
- Dependence on successful clinical trials and regulatory approvals.
- High cash burn rate.
- Limited brand recognition.
What Could Drive LOBEF Stock Higher?
LOBEF catalyst: Initiation of Phase 1 clinical trials for Lobe Sciences' lead drug candidate in Q2 2026.
- Announcement of strategic partnership with a pharmaceutical company in Q3 2026.
- Advancements in the development of novel drug delivery systems for psilocybin-based therapies.
- Increasing awareness and acceptance of psychedelic medicine within the medical community.
- Potential for regulatory changes that could facilitate the development and commercialization of psychedelic therapies.
What Are the Key Risks for LOBEF?
Financial-distress signal — its Altman Z-Score of -13.65 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could delay or halt the development of Lobe Sciences' drug candidates.
- Regulatory hurdles and uncertainty could impede the approval and commercialization of psychedelic therapies.
- Competition from other companies in the psychedelic medicine space could erode Lobe Sciences' market share.
- Negative public perception of psychedelic drugs could limit market adoption.
- The company's high cash burn rate could lead to the need for additional financing, potentially diluting existing shareholders.
What Are the Growth Opportunities for LOBEF?
- Expansion into New Therapeutic Areas: Lobe Sciences has the opportunity to expand its research and development efforts into additional therapeutic areas beyond mTBI and PTSD. This could include exploring the use of psilocybin-based therapies for other mental health conditions such as depression, anxiety, and addiction. The market for these conditions is substantial, with millions of people worldwide affected. Successful expansion into new therapeutic areas could significantly increase Lobe Sciences' market potential and revenue streams. The timeline for this growth opportunity depends on the success of ongoing research and clinical trials, but could materialize within the next 3-5 years.
- Strategic Partnerships with Pharmaceutical Companies: Lobe Sciences can pursue strategic partnerships with established pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could provide access to funding, expertise, and distribution networks. Collaborating with larger pharmaceutical companies could also enhance Lobe Sciences' credibility and visibility within the industry. The timeline for securing such partnerships is uncertain, but ongoing discussions and networking efforts could lead to agreements within the next 1-2 years. This could significantly de-risk the development pathway.
- Development of Novel Drug Delivery Systems: Lobe Sciences' focus on developing devices for the efficient application of medications presents a significant growth opportunity. By creating innovative drug delivery systems, the company can improve the bioavailability and efficacy of its psilocybin-based therapies. This could lead to better patient outcomes and increased market adoption. The development of these systems could also create new revenue streams through licensing or direct sales. The timeline for this growth opportunity depends on the success of ongoing research and development efforts, but could yield results within the next 2-3 years.
- Intellectual Property Protection: Lobe Sciences can strengthen its competitive position by aggressively pursuing intellectual property protection for its drug candidates and drug delivery systems. This includes filing patents for novel formulations, methods of treatment, and device designs. Strong intellectual property protection can create barriers to entry for competitors and enhance the company's long-term value. The timeline for securing patents can vary, but ongoing efforts to protect its innovations should yield results within the next 1-2 years.
- Regulatory Approvals and Commercialization: The ultimate growth opportunity for Lobe Sciences lies in obtaining regulatory approvals for its drug candidates and successfully commercializing them. This would involve completing clinical trials, submitting regulatory filings, and establishing manufacturing and distribution capabilities. Successful commercialization would generate significant revenue and establish Lobe Sciences as a leader in the psychedelic medicine market. The timeline for this growth opportunity is dependent on the success of clinical trials and regulatory reviews, but could materialize within the next 3-5 years.
What Are LOBEF's Competitive Advantages?
- Focus on psychedelic medicine provides a niche market.
- Proprietary formulations combining psilocybin with NAC.
- Development of innovative drug delivery systems.
- Intellectual property protection through patents and trademarks.
- Early mover advantage in the emerging psychedelic medicine market.
What Does LOBEF Do?
Lobe Sciences Ltd., formerly known as Greenstar Biosciences Corp., is a life sciences company dedicated to the research and development of psychedelic medicines. Founded with the vision of addressing unmet medical needs in the treatment of neurological disorders, the company changed its name in November 2020 to reflect its focus on innovative therapies. Lobe Sciences is headquartered in Vancouver, Canada. The company's primary focus is on developing psilocybin-based therapeutics in combination with N-acetylcysteine (NAC) for the treatment of mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD). These conditions represent significant healthcare challenges, with limited effective treatment options currently available. In addition to its pharmaceutical development efforts, Lobe Sciences is also developing devices designed to improve the efficient application of medications. This includes exploring novel drug delivery methods to enhance therapeutic outcomes and patient compliance. The company aims to be a leader in the emerging field of psychedelic medicine, driven by scientific rigor and a commitment to improving patient lives. Lobe Sciences operates within the broader pharmaceutical industry, specifically targeting the specialty and generic drug manufacturing segment. Its competitive positioning is centered on its unique focus on psychedelic compounds and innovative delivery systems.
What Products and Services Does LOBEF Offer?
- Researches and develops psilocybin-based therapeutics.
- Focuses on treatments for mild traumatic brain injuries (mTBI).
- Develops therapies for post-traumatic stress disorder (PTSD).
- Combines psilocybin with N-acetylcysteine (NAC) in its formulations.
- Creates devices for efficient drug application.
- Aims to improve drug delivery methods for better patient outcomes.
- Operates within the emerging psychedelic medicine market.
How Does LOBEF Make Money?
- Develops and patents novel psilocybin-based therapies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approvals from health authorities.
- Potentially partners with pharmaceutical companies for commercialization.
- May license its technologies to other companies.
What Industry Does LOBEF Operate In?
Lobe Sciences Ltd. operates within the rapidly evolving psychedelic medicine industry. This sector is experiencing increased interest due to growing evidence suggesting the therapeutic potential of psychedelic compounds for various mental health conditions. The market is characterized by a mix of established pharmaceutical companies and emerging biotech firms, all vying to develop innovative treatments. Lobe Sciences' focus on mTBI and PTSD positions it within a niche market with significant unmet needs. Competitors include companies like AUSAF (Australis Capital Inc.), BBRRF (BevCanna Enterprises Inc.), BUDZ (Cannabis Strategic Ventures Inc.), CANN (General Cannabis Corp), and CBIH (Clever Leaves Holdings Inc.). The industry faces regulatory challenges and requires rigorous clinical trials to validate the safety and efficacy of psychedelic-based therapies.
Who Are LOBEF's Key Customers?
- Patients suffering from mild traumatic brain injuries (mTBI).
- Individuals diagnosed with post-traumatic stress disorder (PTSD).
- Healthcare providers seeking innovative treatment options.
- Pharmaceutical companies interested in licensing or acquiring new therapies.
- Research institutions involved in psychedelic medicine.
Company Profile
Lobe Sciences Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Frederick Dominick Sancilio. LOBEF has traded publicly since 2023.
How Lobe Sciences Ltd. Is Valued
Lobe Sciences Ltd. carries a market capitalization of $15.9M, placing it in the micro-cap category.
Key Financial Metrics
Its free cash flow yield is -19.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Lobe Sciences Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.65 places it in the distress zone, a signal of elevated financial risk.
LOBEF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on a high-growth market (psychedelic medicine).
- Novel therapeutic approach combining psilocybin with NAC.
- Development of innovative drug delivery systems.
- Experienced management team with expertise in drug development.
Bear Case
- Early-stage company with limited revenue.
- Dependence on successful clinical trials and regulatory approvals.
- High cash burn rate.
- Limited brand recognition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
LOBEF Latest News
No recent news available for LOBEF.
LOBEF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LOBEF.
Price Targets
Wall Street price target analysis for LOBEF.
LOBEF MoonshotScore
What does this score mean?
The MoonshotScore rates LOBEF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Frederick Dominick Sancilio
CEO
Frederick Dominick Sancilio is the Chief Executive Officer of Lobe Sciences Ltd. His background includes extensive experience in the pharmaceutical and life sciences industries. He has held various leadership positions in companies focused on drug development, clinical research, and commercialization. Sancilio's expertise spans across multiple therapeutic areas, including neurology, psychiatry, and pain management. He holds advanced degrees in science and business administration, providing him with a strong foundation in both the scientific and commercial aspects of the pharmaceutical industry.
Track Record: Under Frederick Dominick Sancilio's leadership, Lobe Sciences Ltd. has focused on advancing its research and development programs in psychedelic medicine. Key milestones include the development of novel psilocybin-based formulations and the initiation of clinical trials for mTBI and PTSD. Sancilio has also been instrumental in securing partnerships and funding to support the company's growth initiatives. His strategic decisions have positioned Lobe Sciences as a player in the emerging psychedelic medicine market.
LOBEF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lobe Sciences Ltd. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards, potentially increasing investment risk. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited financial disclosure increases investment risk.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- OTC Other stocks are more susceptible to fraud and manipulation.
- The company may not meet the minimum financial standards of higher-tier exchanges.
- The regulatory oversight of OTC Other stocks is less stringent than that of major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Check for any red flags or warning signs, such as frequent changes in management or auditors.
- Consult with a qualified financial advisor before making any investment decisions.
- Focus on research and development of psychedelic medicines.
- Development of psilocybin-based therapeutics for mTBI and PTSD.
- Efforts to develop innovative drug delivery systems.
- Experienced CEO with a background in the pharmaceutical industry.
- Publicly traded company, subject to some level of regulatory oversight.
Common Questions About LOBEF (Healthcare)
What does Lobe Sciences Ltd. do?
Lobe Sciences Ltd. is a life sciences company focused on the research and development of psychedelic medicines, particularly psilocybin-based therapeutics, for the treatment of mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD). The company is also developing devices for the efficient application of medications.
What do analysts say about LOBEF stock?
As of 2026-03-17, there is no readily available analyst coverage for LOBEF stock due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before making any investment decisions.
What are the main risks for LOBEF?
The main risks for Lobe Sciences Ltd. include the inherent uncertainties of drug development, such as clinical trial failures and regulatory hurdles. The company's reliance on psilocybin-based therapies also exposes it to potential negative public perception and evolving regulatory landscapes.
What are the key factors to evaluate for LOBEF?
Evaluate LOBEF on fundamentals, analyst consensus, and risk factors. Lobe Sciences Ltd. presents a speculative investment opportunity within the emerging psychedelic medicine market. Not financial advice.
How frequently does LOBEF data refresh on this page?
LOBEF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LOBEF's recent stock price performance?
Lobe Sciences Ltd. (LOBEF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a high-growth market (psychedelic medicine). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LOBEF overvalued or undervalued right now?
Lobe Sciences Ltd. (LOBEF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LOBEF before investing?
Before investing in Lobe Sciences Ltd. (LOBEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stocks carry higher risk than exchange-listed stocks.
- The psychedelic medicine market is subject to evolving regulations.